Heidi Ko, Medical Director of Medical Affairs at Labcorp Drug Development, shared a post on LinkedIn:
“We’re excited to be at this year’s 2025 ASCO Annual Meeting to share how our oncology testing solutions are helping providers deliver faster, more personalized care. With a portfolio of over 450 tests – including biomarker testing, hereditary cancer risk assessments, next-generation sequencing (NGS), and molecular disease detection – we support confident decision-making across the continuum of cancer care. Let’s connect in person to explore how we can help you improve patient outcomes.”
More posts featuring Heidi Ko.